Find Grants for Non-profits
Find out if you qualify for verified grants for Non-profits. Discover your eligibility and key funding details for Non-profits from major foundations and government agencies.
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
Deadline: October 8, 2027
Opportunity Number: PAR-25-248
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: October 8, 2027
Status: Posted
CFDA Numbers: 93.393
Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
Deadline: November 18, 2027
Opportunity Number: RFA-DA-26-034
Agency: National Institutes of Health
Open Date: November 20, 2024
Close Date: November 18, 2027
Status: Posted
CFDA Numbers: 93.839, 93.837, 93.840, 93.855, 93.233, 93.279, 93.838
NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)
Deadline: October 14, 2027
Opportunity Number: PAR-25-135
Agency: National Institutes of Health
Open Date: November 20, 2024
Close Date: October 14, 2027
Status: Posted
CFDA Numbers: 93.398
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
Deadline: November 19, 2026
Opportunity Number: PAR-25-052
Agency: National Institutes of Health
Open Date: November 20, 2024
Close Date: November 19, 2026
Status: Posted
CFDA Numbers: 93.853
Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed)
Deadline: September 7, 2027
Opportunity Number: PAR-25-112
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2027
Status: Posted
CFDA Numbers: 93.865, 93.173
Advancement and Innovation in Measurement of Language Development and Predictors (R21 Clinical Trial Not Allowed)
Deadline: September 7, 2027
Opportunity Number: PAR-25-113
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2027
Status: Posted
CFDA Numbers: 93.865, 93.173
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
Deadline: January 7, 2028
Opportunity Number: PAR-25-243
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.393
Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
Deadline: November 16, 2027
Opportunity Number: PAR-25-244
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: November 16, 2027
Status: Posted
CFDA Numbers: 93.393
Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
Deadline: September 7, 2026
Opportunity Number: PAR-25-038
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2026
Status: Posted
CFDA Numbers: 93.242
Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
Deadline: September 7, 2026
Opportunity Number: PAR-25-037
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2026
Status: Posted
CFDA Numbers: 93.242
Investigator Initiated Innovation in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)
Deadline: September 7, 2027
Opportunity Number: PAR-25-228
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2027
Status: Posted
CFDA Numbers: 93.879, 93.172
Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)
Deadline: September 7, 2027
Opportunity Number: PAR-25-229
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2027
Status: Posted
CFDA Numbers: 93.172, 93.879
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Deadline: January 7, 2027
Opportunity Number: PAR-25-069
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: January 7, 2027
Status: Posted
CFDA Numbers: 93.393
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Deadline: January 7, 2027
Opportunity Number: PAR-25-070
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: January 7, 2027
Status: Posted
CFDA Numbers: 93.393
NCMRR Early Career Research Award (R03 Clinical Trial Optional)
Deadline: January 7, 2028
Opportunity Number: PAR-25-124
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.865
NICHD Small Research Grant Program (R03 Clinical Trial Required)
Deadline: January 7, 2028
Opportunity Number: PA-25-125
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.865
NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
Deadline: November 12, 2027
Opportunity Number: PAR-25-204
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: November 12, 2027
Status: Posted
CFDA Numbers: 93.279
NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)
Deadline: January 7, 2028
Opportunity Number: PAR-25-105
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.121
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
Deadline: September 7, 2026
Opportunity Number: PAR-25-065
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2026
Status: Posted
CFDA Numbers: 93.242, 93.866
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
Deadline: September 7, 2026
Opportunity Number: PAR-25-064
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2026
Status: Posted
CFDA Numbers: 93.866, 93.242
Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
Deadline: September 7, 2026
Opportunity Number: PAR-25-039
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2026
Status: Posted
CFDA Numbers: 93.242
Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
Deadline: September 7, 2026
Opportunity Number: PAR-25-040
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2026
Status: Posted
CFDA Numbers: 93.242
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Deadline: November 6, 2026
Opportunity Number: PAR-25-095
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: November 6, 2026
Status: Posted
CFDA Numbers: 93.172, 93.393, 93.866, 93.121
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
Deadline: November 17, 2026
Opportunity Number: PAR-25-096
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: November 17, 2026
Status: Posted
CFDA Numbers: 93.393, 93.121, 93.172, 93.866
Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)
Deadline: September 7, 2026
Opportunity Number: PAR-25-067
Agency: National Institutes of Health
Open Date: November 18, 2024
Close Date: September 7, 2026
Status: Posted
CFDA Numbers: 93.242
